Local Effects of Amino Acids in the Bilaterally Perfused Human Leg
Information source: University of Aarhus
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Critical Illness; Protein Metabolism; Pharmaconutrients
Intervention: Vamin (Fresenius Kabi) (Dietary Supplement)
Status: Active, not recruiting
Sponsored by: University of Aarhus
Official(s) and/or principal investigator(s):
Niels Møller, Professor, Dr.Med., Principal Investigator, Affiliation: University of Aarhus
Introduction: Protein loss during critical illness is an important problem and is shown to
predict overall survival. In animal studies, infusion of leucine is shown to increase the
synthesis of muscle protein by 30-40% and decrease protein degradation by 30%.
Objectives: Compared to saline, an amino acid infusion in the femoral artery will promote
protein synthesis and inhibit breakdown assessed with local a/v phenylalanine and tyrosine
tracer kinetics in healthy volunteers. These effects will include distinct alterations in
muscle signal events, in particular mTOR.
Methods: n = 8 healthy male subjects are equipped with catheters in aa. femorales and vv.
femorales bilaterally under local anaesthetics. Each study comprises a 3-hour basal period
and a 3-hour period with hyperinsulinaemic-euglucaemic clamp. During the test, samples of
arterial and venous blood and 4 muscle biopsies are obtained. The intervention contain
continues saline infusion compared to either amino acids (Vamin).
Perspectives: This study elucidates the direct effect of aminoacids on muscle protein
metabolism in humans and contribute to further development of nutritional therapy in human
Official title: Local Effects of Amino Acids in the Bilaterally Perfused Human Leg
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Primary outcome: Changes in muscle metabolism after administration of amino acids.
Secondary outcome: Intracellular mTOR and pAkt signal activation after infusion of amino acids.
Minimum age: 18 Years.
Maximum age: 50 Years.
- BMI between 19 and 28
- Written consent before study start
- Inclusion in other studies using ionizing radiation.
- Allergic to egg or soy
Locations and Contacts
M-researchlab. MEA, Aarhus University Hospital, NBG, Aarhus C 8000, Denmark
Starting date: September 2011
Last updated: August 5, 2013